Advertisement

Drugs & Therapy Perspectives

, Volume 19, Issue 8, pp 5–6 | Cite as

Clozapine in prevention of suicide in patients with schizophrenia: profile report

  • Michael Sernyak
Drugs and Profile Reports

Keywords

Schizophrenia Clozapine Olanzapine Suicide Attempt Antipsychotic Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Wagstaff AJ, Perry CM. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs 2003; 17(4): 273–80PubMedCrossRefGoogle Scholar
  2. 2.
    Sernyak M. Clozapine and prevention of suicide in schizophrenia: a viewpoint. CNS Drugs 2003; 17(4): 281–2CrossRefGoogle Scholar
  3. 3.
    Wagstaff AJ, Bryson HM. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995; 4(5): 370–400CrossRefGoogle Scholar
  4. 4.
    Masellis M, Basile VS, Özdemir V, et al. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry 2000 Feb 1; 47(3): 252–66PubMedCrossRefGoogle Scholar
  5. 5.
    Edge SC, Markowitz JS, Devane CL. Clozapine drug-drug interactions: a review of the literature. Hum Psychopharmacol 1997 Jan; 12: 5–20CrossRefGoogle Scholar
  6. 6.
    Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82–91PubMedCrossRefGoogle Scholar
  7. 7.
    Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998 Jul; 21(4): 245–50PubMedGoogle Scholar
  8. 8.
    Ciapparelli A, Dell’Osso L, Pini S, et al. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000 May; 61(5): 329–34PubMedCrossRefGoogle Scholar
  9. 9.
    Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995 Feb; 152(2): 183–90PubMedGoogle Scholar
  10. 10.
    Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 2000 Jun; 20(3): 325–7PubMedCrossRefGoogle Scholar
  11. 11.
    Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998 Aug; 49(8): 1029–33PubMedGoogle Scholar
  12. 12.
    Sernyak MJ, Desai R, Stolar M, et al. Impact of clozapine on completed suicide. Am J Psychiatry 2001 Jun; 158(6): 931–7PubMedCrossRefGoogle Scholar
  13. 13.
    Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997 Nov; 8(6): 671–7PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Michael Sernyak
    • 1
  1. 1.Yale School of MedicineWest HavenUSA

Personalised recommendations